- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05651022 | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Indaptus Therapeutics, IncINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 |
| clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT07152353 | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan) | active not recruiting | N/A | 47 | Ion Beam ApplicationsINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT02215928 | Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors | recruiting | — | 100 | Stanford UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05631899 | CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06504368 | Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | recruiting | Phase 1 | 32 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04643418 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 81 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04954599 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | recruiting | Phase 1 / Phase 2 | 126 | Maastricht University Medical CenterOTHER | 3 | Oct 7, 2025 | clinicaltrials |
| NCT05055609 | Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | recruiting | Phase 1 | 94 | TretheraINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT03772561 | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies(MEDIPAC) | recruiting | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT01843413 | Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | active not recruiting | Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05354323 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | active not recruiting | Phase 1 | 6 | NEC OncoImmunity ASINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05481502 | An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors(PIONEER) | recruiting | N/A | 160 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06916442 | Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy(GZMB_PET) | not yet recruiting | — | 200 | Zhongnan HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06897228 | PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors | recruiting | Phase 1 | 18 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06350539 | Personalized Models for Cancer Research | recruiting | — | 500 | New York Stem Cell Foundation Research InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06032845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)(CASTLE-11) | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04643574 | NeoTIL in Advanced Solid Tumors | active not recruiting | Phase 1 | 42 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05662397 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | active not recruiting | Phase 1 / Phase 2 | 77 | HotSpot Therapeutics, IncINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT06436157 | A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention(GENESIS) | recruiting | N/A | 60 | University of California, DavisOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06026254 | A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | active not recruiting | Phase 1 | 2 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06003621 | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients(MoST-TAP) | recruiting | Phase 2 | 96 | OmicoOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06622486 | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 50 | Egle TherapeuticsINDUSTRY | 2 | Nov 7, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06090513 | Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients | not yet recruiting | — | 300 | Bien-Willner Physicians Group PAOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06477614 | Anti-cancer DC Cell Vaccination to Treat Solid Tumors | recruiting | Phase 1 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06478108 | Interventional Software for Multi-immunotherapy of Solid Tumors | recruiting | Phase 2 / Phase 3 | 60 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06195293 | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06195384 | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06196294 | GPC3/Mesothelin-CAR-γδT Cells Against Cancers | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04803318 | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jan 13, 2026source: clinicaltrials